Patents by Inventor Ari Zimran
Ari Zimran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210260100Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: February 10, 2021Publication date: August 26, 2021Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
-
Publication number: 20200281961Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: February 26, 2020Publication date: September 10, 2020Applicant: ENZO THERAPEUTICS, INC.Inventors: Yaron ILAN, Maya MARGALIT, Ari ZIMRAN
-
Patent number: 10639324Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: GrantFiled: October 30, 2018Date of Patent: May 5, 2020Assignee: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
-
Publication number: 20190254992Abstract: Provided are therapeutic combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, as well as compositions, kits and methods using the same in treating disorders associated with protein misfolding and for immunomodulation.Type: ApplicationFiled: June 29, 2017Publication date: August 22, 2019Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, SHAARE ZEDEK SCIENTIFIC LTD.Inventors: David ARKADIR, Yaron ILAN, Ari ZIMRAN
-
Patent number: 10265412Abstract: The present invention relates in general to the field of enzyme replacement therapy, and specifically to chimeric proteins including protein hormone-therapeutic protein conjugates and fusion proteins, wherein the protein hormone is selected from a protein hormone which is able to cross the blood brain barrier, for the treatment of lysosomal storage diseases, compositions of the same and to methods of use thereof.Type: GrantFiled: February 6, 2007Date of Patent: April 23, 2019Assignees: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science, The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventors: Naftali Stern, Ruth Navon, Anthony Futerman, Ari Zimran, Etty Osher
-
Publication number: 20190060353Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: October 30, 2018Publication date: February 28, 2019Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
-
Publication number: 20180042959Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: June 12, 2017Publication date: February 15, 2018Applicant: ENZO THERAPEUTICS, INC.Inventors: YARON ILAN, MAYA MARGALIT, ARI ZIMRAN
-
Publication number: 20180036326Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: October 11, 2017Publication date: February 8, 2018Applicant: ENZO THERAPEUTICS, INC.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran, Elazar Rabbani, Dean L. Engelhardt
-
Patent number: 9717754Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: GrantFiled: September 30, 2003Date of Patent: August 1, 2017Assignee: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
-
Publication number: 20170042921Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: October 11, 2016Publication date: February 16, 2017Applicant: Enzo Therapeutics, Inc.Inventors: Yaron ILAN, Maya Margalit, Ari Zimran, Elazar Rabbani, Dean L. Engelhardt
-
Publication number: 20100183577Abstract: The present invention relates in general to the field of enzyme replacement therapy, and specifically to chimeric proteins including protein hormone-therapeutic protein conjugates and fusion proteins, wherein the protein hormone is selected from a protein hormone which is able to cross the blood brain barrier, for the treatment of lysosomal storage diseases, compositions of the same and to methods of use thereof.Type: ApplicationFiled: February 6, 2007Publication date: July 22, 2010Inventors: Naftali Stern, Ruth Navon, Anthony Futerman, Ari Zimran, Etty Osher
-
Publication number: 20040171522Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: February 27, 2003Publication date: September 2, 2004Inventors: Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran
-
Publication number: 20040171527Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: December 10, 2003Publication date: September 2, 2004Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran
-
Publication number: 20040171528Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: December 10, 2003Publication date: September 2, 2004Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran
-
Publication number: 20040171557Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: September 30, 2003Publication date: September 2, 2004Inventors: Yaron Iian, Maya Margalit, Ari Zimran
-
Publication number: 20040171526Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: December 10, 2003Publication date: September 2, 2004Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran